Star Lake Bioscience Co., Inc. Class A

Star Lake Bioscience Co., Inc. Class A

SSSE:600866
4.32
CNY
+0.06
(+1.41%)
0.01EPS
353.95P/E
6.96BMarket Cap
Apr 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.78
1.57
1.12
1.12
1.09
1.42
1.4
1.51
5.05
14.72
10.46
10.43
9.57
9.71
Basic EPS, GAAP
0.04
-0.65
-0.65
0.04
-0.25
0.07
0.2
0.2
0.19
0.51
0.41
0.57
0.59
0.01
Free Cash Flow per Basic Share
-0.26
-0.12
-0.16
- -
0.01
0.03
0.07
-0.05
-0.23
1.02
0.99
1.06
-0.45
- -
Dividend per Share
0.13
0.1
0.06
0.06
0.05
0.03
0.02
0.02
0.11
0.31
0.09
0.45
0.44
0.44
Book Value per Share
2.68
2.29
1.62
1.66
1.42
1.48
2.06
2.26
5.45
4.14
4.55
4.74
4.95
4.6
Tangible Book Value per Share
2.32
2
1.36
1.5
1.23
1.3
1.59
1.77
4.18
3.6
4.08
4.31
4.53
4.18
Basic Weighted Avg Shares
506
555
650
608
633
604
748
739
807
1,188
1,662
1,661
1,661
1,662
Sales/Revenue/Turnover
903
871
730
680
687
859
1,050
1,116
4,071
17,486
17,374
17,334
15,900
16,130
Operating Margin (%)
-13.51
-14.11
-17.7
2.03
-1.93
9.01
17.67
15.62
7.97
10.63
7.11
9.43
8.09
1.03
Depreciation Expense
154
147
127
81
79
79
87
88
104
982
854
846
851
- -
Net Income, GAAP
20
-361
-422
24
-158
42
150
149
152
608
678
943
979
20
Effective Tax Rate (%)
36.29
- -
- -
13.14
- -
- -
4.97
5.06
10.49
16.9
20.6
22.97
20.37
48.38
Profit Margin (%)
2.24
-41.4
-57.88
3.58
-23.04
4.92
14.25
13.32
3.74
3.48
3.9
5.44
6.16
0.12
Working Capital
554
571
279
159
98
143
284
172
-2,384
-1,017
282
677
-277
-1,888
LT Debt
675
383
307
35
105
93
21
156
798
1,534
1,761
1,763
2,429
2,367
Total Equity
1,465
1,468
1,048
1,072
914
956
1,520
1,669
6,921
6,929
7,659
8,031
8,452
7,869
Return on Invested Capital (%)
-3.38
- -
- -
0.97
- -
3.49
9.99
7.6
3.7
10.25
5.84
8.05
7.27
-0.04
Return on Capital (%)
2.91
- -
- -
3.5
- -
4.63
10.49
8.21
1
2.06
6.94
8.75
8.04
0.39
Return on Common Equity (%)
1.36
-24.48
-33.47
2.29
-15.93
4.52
12.08
9.33
5.34
11.15
9.39
12.22
12.16
0.25

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3,476
5,084
5,413
LT Borrowings
2,584
2,080
2,316
LT Finance Leases
67
52
51
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,661
1,661
1,661
Market Capitalization
11,846
7,294
6,962

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,927
6,714
6,356
Cash, Cash Equivalents & STI
1,109
1,506
1,819
Accounts Receivable, Net
814
939
866
Inventories
2,919
2,969
2,358
Total Current Liabilities
6,103
8,380
8,244
Payables & Accruals
- -
- -
- -
ST Debt
3,476
5,084
5,413
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
39.64%
67.09%
5.23%
Free Cash Flow
44.89%
-102.16%
-142.43%
Net Income, GAAP
-37.39%
71.3%
3.79%
Sales/Revenue/Turnover
63.29%
117.02%
-8.27%
Total Cash Common Dividend
102.36%
216.59%
-2.44%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,200
4,287
4,303
4,545
17,334
2025
4,039
4,120
- -
3,823
15,900
2026
3,740
4,449
4,119
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.15
0.1
0.16
0.57
2025
0.29
0.22
- -
-0.02
0.59
2026
-0.03
0.07
-0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.4
0.02
0.01
0.45
2025
0.01
0.39
- -
- -
0.44
2026
0.02
0.02
0.4
- -
- -

Company Description

CEO
Xiao Lin Yan
Full Time Employees
10,528
Sector
Consumer non-durables
Industry
Food: specialty/candy
Address
No.67 Gongnong North Road Zhaoqing GD China 526040
IPO Date
Aug 18, 1994
Business
Star Lake Bioscience Co., Inc. Zhaoqing Guangdong (600866.SS) manufactures and markets biochemical pharmaceuticals, food additives, and feed additives utilizing biological fermentation and biochemical engineering technologies; core products include pharmaceutical intermediates and APIs such as inosine, ribavirin, L-proline, guanosine, adenosine, adenine, adefovir dipivoxil tablets, memantine hydrochloride, arginine, and D-ribose under the Yue Bao brand; food additives encompassing disodium 5'-ribonucleotide (I+G), disodium 5'-inosinate (IMP), disodium 5'-guanylate (GMP), and fructose syrups (F55, F42, F60) under the Star Lake brand; and feed additives like L-valine, L-threonine, and L-lysine under the Star Lake brand. The company, founded in 1964 as Zhaoqing Agricultural Microorganism Factory and listed on the Shanghai Stock Exchange in 1994, maintains headquarters in Zhaoqing, Guangdong province, China, with primary operations in China and international markets serving pharmaceutical firms, food processors, and animal feed producers. Recent developments encompass the completion of its acquisition of a 99.22% stake in Ningxia EPPEN Biotech Co., Ltd. in November 2022 for approximately CNY 5.376 billion to bolster biotechnology capabilities; plans in 2025 to issue over 146 million shares for fundraising; investment of up to CNY 3.30 billion in a new amino acid production facility; a 65.2% net profit increase in the first half of 2025 amid revenue of CNY 8.16 billion; and a 39.12% rise in 2024 net profits with an 88.55% surge in Q1 2025 earnings.